Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat + R-CEP in Elderly Relapsed DLBCL
NCT00667615Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2008
- Primary completion
- Feb 2017
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorinostat in diffuse large B-cell lymphoma (DLBCL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Apr 2008; status: completed.
02
Drugs
vorinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00667615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00667615.